drugset / Trial / NCT06335147
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of PD1 monoclonal antibody combined with mFOLFOX6 neoadjuvant therapy for advanced resectable metastatic colon cancer with enriched pro-inflammatory pan macrophage subpopulations
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Serplulimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | Serplulimab | Monoclonal antibody | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |